Skip to main content

Consultancy on the economic implications of a genomically guided approach to cancer care in Australia

Project Member(s): Viney, R., Hall, J., Van Gool, K., De Abreu Lourenco, R., Haywood, P.

Funding or Partner Organisation: The Cancer Council NSW

Start year: 2015

Summary: 1. Describe the costs and benefits to Australia¿s healthcare system of introducing genomically-guided cancer care, including clear specifications of current areas of uncertainty and directions for further research that will meaningfully contribute to the evidence base in this area. 2. Develop an economic model that identifies the main drivers of costs and outcomes, that can be used as a policy tool, and that can be updated and recast as new data and estimates change.


Daniels, B, Lord, S, Kiely, B, Houssami, N, Lu, C, Ward, R, Haywood, P & Pearson, S 2017, 'Use and outcomes of targeted therapies in early and metastatic HER2–positive breast cancer in Australia: Protocol detailing observations in a whole of population cohort', BMJ Open, vol. 7, pp. 1-12.
View/Download from: Publisher's site

De Abreu Lourenco, R, Haywood, P, Parkinson, B, van Gool, K & Viney, R CHERE 2015, The economic implications of a genomically guided approach to cancer: A report by the Centre for Health Economics Research and Evaluation for the Cancer Council, Sydney.

Keywords: genomically guided cancer care, economic model

FOR Codes: Health Policy Evaluation, Health Policy Economic Outcomes, Health Economics